SSG
RPRX icon

Summit Securities Group’s Royalty Pharma RPRX Stock Holding History

Summit Securities Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,163
Closed -$36.2K – 1384
2025
Q1 		$36.2K Buy
+1,163
New +$36.9K 0.01% 373
2023
Q2 		– Sell
-1
Closed – – 1060
2023
Q1 		$0 Hold
1
– – ﹤0.01% 1210
2022
Q4 		$0 Buy
+1
New +$42 ﹤0.01% 1345
2022
Q2 		– Sell
-50
Closed -$2K – 1190
2022
Q1 		$2K Buy
+50
New +$1.96K ﹤0.01% 1049

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Summit Securities Group's RPRX Position: Q2 2025 in Review

Summit Securities Group sold out of Royalty Pharma (RPRX) in Q2 2025, closing a stake of 1,163 shares — an estimated $36.2K sold.

Summit Securities Group first reported a position in RPRX in Q1 2022 and held it in 4 quarters. The position peaked at $36.2K in Q1 2025. 454 funds tracked by Wall St. Rank hold RPRX as of Q2 2025.

  • Summit Securities Group reported no remaining Royalty Pharma position as of Q2 2025 after selling out during the quarter.
  • Summit Securities Group sold 1,163 Royalty Pharma shares in Q2 2025, an estimated $36.2K.
  • Summit Securities Group first reported a position in Royalty Pharma in Q1 2022 and held it in 4 quarters.
  • Summit Securities Group's Royalty Pharma position peaked at $36.2K in Q1 2025.
  • 454 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2025.

Based on Summit Securities Group's 13F filing for Q2 2025, filed 12 Aug 2025.